The continuance intention to vaccinate against COVID-19: An empirical study from Malaysia.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

COVID-19*/prevention & control ; COVID-19*/epidemiology ; COVID-19*/psychology ; COVID-19*/virology ; COVID-19 Vaccines*/administration & dosage ; Intention* ; Vaccination*/psychology; Humans ; Malaysia/epidemiology ; Female ; Male ; Adult ; Middle Aged ; Surveys and Questionnaires ; SARS-CoV-2 ; Young Adult ; Adolescent ; Health Belief Model ; Aged ; Pandemics/prevention & control

Background: Vaccination has been one of the most effective preventive strategies to contain the COVID-19 pandemic. However, as the COVID-19 vaccines' effect wanes off after some time and given their reduced level of protection against mutation strains of the virus, the calls for boosters and second boosters signal the need for continuous vaccination for the foreseeable future. As Malaysia transitions into the endemic phase, the nation's ability to co-exist with the virus in the endemic phase will hinge on people's continuance intention to be vaccinated against the virus. Adapting the expectations confirmation model (ECM) to the public health context and in a developing country, this study integrates the ECM with the health belief model (HBM) and the theory of reasoned action (TRA) to examine the inter-relationships of the predictors of people's continuance intention to vaccinate against COVID-19.
Methodology: Data were collected using self-administered questionnaires from 1,914 respondents aged 18 and above by a marketing consulting firm via its online panel. The partial least squares structural equation modeling (PLS-SEM) technique was used to analyze the data.
Results: Out of the 1,914 respondents, 55.9% reported having a continuance intention to vaccinate against COVID-19, similar to other developing countries. The multivariate analysis revealed that perceived usefulness and satisfaction significantly influenced individuals' continuance intention to vaccinate against COVID-19. Additionally, attitude was found to play a key role in influencing behavioral change among individuals towards their perceptions of continuously getting vaccinated against COVID-19.
Conclusions: By integrating three theoretical frameworks (i.e., HBM, TRA and ECM), this study showed that behavioral characteristics could provide insights towards continuance vaccination intention. Hence, policymakers and key stakeholders can develop effective public health strategies or interventions to encourage vaccine booster uptake by targeting behavioral factors such as perceived usefulness, attitude, satisfaction, and subjective norms.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Hwang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Vaccines (Basel). 2022 Aug 17;10(8):. (PMID: 36016224)
BMC Public Health. 2022 Feb 4;22(1):229. (PMID: 35120486)
Lancet. 2021 Jul 31;398(10298):385-387. (PMID: 34274038)
Front Microbiol. 2020 Jul 14;11:1526. (PMID: 32760367)
Econ Hum Biol. 2022 Apr;45:101116. (PMID: 35193043)
Lancet. 2021 Oct 30;398(10311):1547-1551. (PMID: 34619099)
N Engl J Med. 2021 Nov 4;385(19):1761-1773. (PMID: 34525277)
Crit Rev Clin Lab Sci. 2022 Jan;59(1):66-75. (PMID: 34598660)
Vaccines (Basel). 2021 Nov 19;9(11):. (PMID: 34835289)
Nature. 2020 Dec;588(7837):205-206. (PMID: 33288887)
N Engl J Med. 2022 Mar 10;386(10):933-941. (PMID: 35020982)
J Health Commun. 2015;20(1):69-79. (PMID: 24870976)
PLoS One. 2022 Jul 20;17(7):e0271625. (PMID: 35857813)
Lancet Respir Med. 2023 May;11(5):395-396. (PMID: 37080227)
J Med Virol. 2022 May;94(5):2181-2187. (PMID: 35075651)
Hum Vaccin Immunother. 2022 Nov 30;18(5):2049169. (PMID: 35417663)
Healthcare (Basel). 2021 Nov 17;9(11):. (PMID: 34828612)
N Engl J Med. 2021 Jul 8;385(2):187-189. (PMID: 33951357)
Hum Vaccin Immunother. 2020 Sep 1;16(9):2204-2214. (PMID: 32730103)
Vaccines (Basel). 2022 Jan 02;10(1):. (PMID: 35062729)
Vaccine. 2021 Nov 26;39(48):6984-6989. (PMID: 34763949)
Int J Environ Health Res. 2022 Apr;32(4):850-861. (PMID: 32741205)
Innov Pharm. 2012;3(2):1-11. (PMID: 22844651)
Vaccines (Basel). 2022 Jan 19;10(2):. (PMID: 35214605)
Sci Rep. 2022 May 19;12(1):8452. (PMID: 35589930)
N Engl J Med. 2022 Apr 21;386(16):1532-1546. (PMID: 35249272)
Vaccine. 2022 Dec 12;40(52):7515-7519. (PMID: 36371369)
PLoS One. 2022 May 23;17(5):e0268926. (PMID: 35604921)
Vaccines (Basel). 2021 Nov 10;9(11):. (PMID: 34835238)
Vaccines (Basel). 2022 Mar 26;10(4):. (PMID: 35455264)
Vaccines (Basel). 2022 Apr 15;10(4):. (PMID: 35455371)
Appl Psychol Health Well Being. 2021 May;13(2):469-484. (PMID: 33634930)
Sci Rep. 2022 Jun 4;12(1):9332. (PMID: 35661125)
J Pharm Policy Pract. 2022 Mar 28;15(1):26. (PMID: 35346377)
Hum Vaccin Immunother. 2021 Dec 2;17(12):4954-4963. (PMID: 34893013)
Vaccines (Basel). 2023 Mar 09;11(3):. (PMID: 36992207)
PLoS One. 2023 Mar 15;18(3):e0282520. (PMID: 36920970)
Patient Educ Couns. 2021 Aug;104(8):1878-1886. (PMID: 33632632)
Hum Vaccin Immunother. 2022 Nov 30;18(5):2065824. (PMID: 35594528)
Lancet Infect Dis. 2022 Mar;22(3):297. (PMID: 35151377)
Lancet Public Health. 2022 May;7(5):e427-e436. (PMID: 35461593)
Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):15530-15535. (PMID: 32554604)
Vaccines (Basel). 2022 Jun 30;10(7):. (PMID: 35891225)
Int J Environ Res Public Health. 2022 Apr 22;19(9):. (PMID: 35564481)
BMC Public Health. 2021 Jun 12;21(1):1129. (PMID: 34118897)
Vaccines (Basel). 2021 Nov 05;9(11):. (PMID: 34835217)
JAMA. 2022 Jan 25;327(4):327-328. (PMID: 35006269)
Hum Vaccin Immunother. 2022 Nov 30;18(5):2078634. (PMID: 35648441)
Vaccines (Basel). 2022 Mar 09;10(3):. (PMID: 35335042)

0 (COVID-19 Vaccines)

Date Created: 20240430 Date Completed: 20240430 Latest Revision: 20240502

20240502

PMC11060549

10.1371/journal.pone.0301383

38687718